Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.
A first-in-class immunoglobulin G4 (IgG4) antibody targeting CD47 has demonstrated durable responses when used in combination with rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or indolent lymphoma.
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
A fixed single‐dose of netupitant 300 mg plus palonosetron 0.50 mg (NEPA) was better than palonosetron and aprepitant in preventing acute and delayed* chemotherapy-induced nausea and vomiting (CINV) following multiple chemotherapy cycles, according to the results of two phase III trials.
The addition of radiation therapy to chemotherapy does not provide a relapse-free survival (RFS) advantage over chemotherapy only in stage III or IVA endometrial cancer, according to the phase III GOG 258* trial.
A complete response to dabrafenib and trametinib treatment in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations leads to greater survival outcomes at 5 years, according to an analysis of data from the COMBI-d* and COMBI-v** trials.
Patients with non–small-cell lung cancer (NSCLC) who underwent radiotherapy had a high risk for major adverse cardiac events (MACE) within 2 years post-therapy, with the cardiac radiation dose exposure being an independent predictor of MACE and all-cause mortality, a large retrospective study shows.
Use of olaparib in the maintenance setting prolongs progression-free survival in patients with a germline BRCA mutation and metastatic pancreatic cancer as compared with placebo, according to the results of the phase III POLO trial.